AB vs CNS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

AB

35.4
AI Score
VS
CNS Wins

CNS

43.0
AI Score

Investment Advisor Scores

AB

35score
Recommendation
AVOID NEW MONEY

CNS

43score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric AB CNS Winner
Forward P/E 8.8339 18.5874 AB
PEG Ratio 0.6343 1.3563 AB
Revenue Growth -40.3% 11.1% CNS
Earnings Growth -0.7% 0.0% CNS
Tradestie Score 35.4/100 43.0/100 CNS
Profit Margin 0.0% 28.2% CNS
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD CNS

Relative Price Performance (Last 90 Days)

AB 1M: -3.7% · 3M: -7.5% CNS 1M: +3.4% · 3M: -14.4%

Current Technical Phase

AB

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.2%), weak momentum, RSI 33

RSI (14): 33.2 · Price: $33.49

CNS

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 46

RSI (14): 46.1 · Price: $71.35

Fundamentals Snapshot

Metric AB CNS
Market Cap — —
Forward P/E 9.1 19.3
Trailing P/E 10.0 22.0
Revenue (TTM) — —
Revenue Growth -0.4% 0.1%
Gross Margin 1.0% 0.5%
Operating Margin 0.0% 0.3%
EPS 3.37 3.25
Dividend Yield 0.10% 0.04%

Frequently Asked Questions

Based on our detailed analysis, CNS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.